|
Title
|
Dexamethasone Posterior Segment
Drug Delivery System (DEX PS DDS) for Diabetic Macular Edema
|
|
MEEI Protocol ID |
05-03-014 |
|
Condition
|
Diabetic Macular Edema
|
|
Sponsor
|
Allergan
|
|
Principal Investigator
|
Lucy Young, M.D.
|
|
Study Design
|
This is a Phase III, Multi-center, Masked, Randomized, Sham-Controlled Trial
|
|
Study Objective
|
To evaluate the safety and efficacy of the DEX PS DDS drug delivery system compared with a Sham DEX PS DDS drug delivery system in patients with diabetic macular edema
|
|
Who is Eligible
|
Patients with diabetic macular edema
|
|
Subject Enrollment
|
This study is currently in follow-up. No new patients can be enrolled.
|
|
Study Procedures
|
Patients may receive up to 7 treatments, at 6 month intervals, during the study period. Patients will be assessed for re-treatment every 3 months.
|
|
For More Information
|
Patricia Houlihan, Study Coordinator
617-573-3646
|
Click here to return to the Ophthalmology Clinical Research page.
Page updated 3/20/2012.
